The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
Clinical trial NCT01899742 · COMPLETED
Trial details
- NCT number
- NCT01899742
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-15
- Primary completion
- 2015-07-22
- Enrollment
- 497
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.